Skip Nav Destination
Issues
15 November 2022
-
Cover Image
Cover Image
The cover shows an FFPE section of pancreatic ductal adenocarcinoma (PDAC, tumor cells in cyan). Opal multiplex immunofluorescence staining shows expression of the chemokine receptor CXCR4 (yellow) on tumor-infiltrating lymphocytes together with CD8+ T cells (green) and macrophages (CD68, red). For details, see the article by Kocher and colleagues on page 4957 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR Drug Updates
FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease–Associated Tumors
Jaleh Fallah; Michael H. Brave; Chana Weinstock; Gautam U. Mehta; Diana Bradford; Haley Gittleman; Erik W. Bloomquist; Rosane Charlab; Salaheldin S. Hamed; Claudia P. Miller; Sarah E. Dorff; Wiley A. Chambers; Bronwyn D. Mixter; Jeannette Dinin; William F. Pierce; Tiffany K. Ricks; Shenghui Tang; Martha Donoghue; Richard Pazdur; Laleh Amiri-Kordestani; Amna Ibrahim; Julia A. Beaver
Review
Special Report
Electronic Nicotine Delivery Systems: An Updated Policy Statement from the American Association for Cancer Research and the American Society of Clinical Oncology
Roy S. Herbst; Dorothy Hatsukami; Dana Acton; Meredith Giuliani; Allyn Moushey; Jonathan Phillips; Shimere Sherwood; Benjamin A. Toll; Kasisomayajula Viswanath; Nicholas J.H. Warren; Graham W. Warren; Anthony J. Alberg
Clinical Trials: Targeted Therapy
Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors
Emerson A. Lim; Johanna C. Bendell; Gerald S. Falchook; Todd M. Bauer; Charles G. Drake; Jennifer H. Choe; Daniel J. George; Janet L. Karlix; Susanna Ulahannan; Kris F. Sachsenmeier; Deanna L. Russell; Ganesh Moorthy; Ben S. Sidders; Elizabeth A. Pilling; Huifang Chen; Maureen M. Hattersley; Mayukh Das; Rakesh Kumar; Gayle P. Pouliot; Manish R. Patel
Clinical Trials: Immunotherapy
A Therapeutic Antigen-Presenting Cell-Targeting DNA Vaccine VB10.16 in HPV16-Positive High-Grade Cervical Intraepithelial Neoplasia: Results from a Phase I/IIa Trial
Peter Hillemanns; Agnieszka Denecke; Linn Woelber; Gerd Böhmer; Matthias Jentschke; Karoline W. Schjetne; Karsten M.H. Bruins Slot; Agnete B. Fredriksen
Precision Medicine and Imaging
PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC
Karlijn Hummelink; Vincent van der Noort; Mirte Muller; Robert D. Schouten; Ferry Lalezari; Dennis Peters; Willemijn S.M.E. Theelen; Viktor H. Koelzer; Kirsten D. Mertz; Alfred Zippelius; Michel M. van den Heuvel; Annegien Broeks; John B.A.G. Haanen; Ton N. Schumacher; Gerrit A. Meijer; Egbert F. Smit; Kim Monkhorst; Daniela S. Thommen
ImmunoPET Imaging with 89Zr-Labeled Atezolizumab Enables In Vivo Evaluation of PD-L1 in Tumorgraft Models of Renal Cell Carcinoma
Aditi Mulgaonkar; Roy Elias; Layton Woolford; Bing Guan; Kien Nham; Payal Kapur; Alana Christie; Vanina T. Tcheuyap; Nirmish Singla; I. Alex Bowman; Christina Stevens; Guiyang Hao; James Brugarolas; Xiankai Sun
SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis–Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer
Umang Swami; Ryon P. Graf; Roberto H. Nussenzveig; Virginia Fisher; Hanna Tukachinsky; Alexa B. Schrock; Gerald Li; Jeffrey S. Ross; Nicolas Sayegh; Nishita Tripathi; Vinay Mathew Thomas; Geoffrey R. Oxnard; Emmanuel S. Antonarakis; Neeraj Agarwal
Family History of Prostate and Breast Cancer Integrated with a Polygenic Risk Score Identifies Men at Highest Risk of Dying from Prostate Cancer before Age 75 Years
Anna Plym; Yiwen Zhang; Konrad H. Stopsack; Yon Ho Jee; Fredrik Wiklund; Adam S. Kibel; Peter Kraft; Edward Giovannucci; Kathryn L. Penney; Lorelei A. Mucci
Translational Cancer Mechanisms and Therapy
Interactions in CSF1-Driven Tenosynovial Giant Cell Tumors
David G.P. van IJzendoorn; Magdalena Matusiak; Gregory W. Charville; Geert Spierenburg; Sushama Varma; Deana R.C. Colburg; Michiel A.J. van de Sande; Kirsten van Langevelde; David G. Mohler; Kristen N. Ganjoo; Nam Q. Bui; Raffi S. Avedian; Judith V.M.G. Bovée; Robert Steffner; Robert B. West; Matt van de Rijn
Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes
Kelly L. Bolton; Denise Chen; Rosario Corona de la Fuente; Zhuxuan Fu; Rajmohan Murali; Martin Köbel; Yanis Tazi; Julie M. Cunningham; Irenaeus C.C. Chan; Brian J. Wiley; Lea A. Moukarzel; Stacey J. Winham; Sebastian M. Armasu; Jenny Lester; Esther Elishaev; Angela Laslavic; Catherine J. Kennedy; Anna Piskorz; Magdalena Sekowska; Alison H. Brand; Yoke-Eng Chiew; Paul Pharoah; Kevin M. Elias; Ronny Drapkin; Michael Churchman; Charlie Gourley; Anna DeFazio; Beth Karlan; James D. Brenton; Britta Weigelt; Michael S. Anglesio; David Huntsman; Simon Gayther; Jason Konner; Francesmary Modugno; Kate Lawrenson; Ellen L. Goode; Elli Papaemmanuil
Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets
Florian Kocher; Alberto Puccini; Gerold Untergasser; Agnieszka Martowicz; Kai Zimmer; Andreas Pircher; Yasmine Baca; Joanne Xiu; Johannes Haybaeck; Piotr Tymoszuk; Richard M. Goldberg; Angelica Petrillo; Anthony F. Shields; Mohamed E. Salem; John L. Marshall; Michael Hall; W. Michael Korn; Chadi Nabhan; Francesca Battaglin; Heinz-Josef Lenz; Emil Lou; Su-Pin Choo; Chee-Keong Toh; Silvia Gasteiger; Renate Pichler; Dominik Wolf; Andreas Seeber
Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks
Anthony R. Cillo; Elina Mukherjee; Nathanael G. Bailey; Sayali Onkar; Jessica Daley; Claudia Salgado; Xiang Li; Dongyan Liu; Sarangarajan Ranganathan; Melissa Burgess; John Sembrat; Kurt Weiss; Rebecca Watters; Tullia C. Bruno; Dario A.A. Vignali; Kelly M. Bailey
Plasma CD27, a Surrogate of the Intratumoral CD27–CD70 Interaction, Correlates with Immunotherapy Resistance in Renal Cell Carcinoma
Nadine Benhamouda; Ikuan Sam; Nicolas Epaillard; Alain Gey; Letuan Phan; Hang Phuong Pham; Nadège Gruel; Antonin Saldmann; Joséphine Pineau; Milena Hasan; Valentin Quiniou; Camille Nevoret; Virginie Verkarre; Valentina Libri; Sebastien Mella; Clémence Granier; Chloe Broudin; Patrice Ravel; Eléonore De Guillebon; Laetitia Mauge; Dominique Helley; Bernd Jabla; Nathalie Chaput; Laurence Albiges; Sandrine Katsahian; Julien Adam; Arnaud Mejean; Olivier Adotevi; Yann A. Vano; Stéphane Oudard; Eric Tartour
De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial
Oleg Gluz; Ulrike Nitz; Cornelia Kolberg-Liedtke; Aleix Prat; Matthias Christgen; Sherko Kuemmel; Mohammad Parsa Mohammadian; Daniel Gebauer; Ronald Kates; Laia Paré; Eva-Maria Grischke; Helmut Forstbauer; Michael Braun; Mathias Warm; John Hackmann; Christoph Uleer; Bahriye Aktas; Claudia Schumacher; Rachel Wuerstlein; Monika Graeser; Enrico Pelz; Katarzyna Jóźwiak; Christine zu Eulenburg; Hans Heinrich Kreipe; Nadia Harbeck; on behalf of the ADAPT TN investigators
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds